Roche shares fall sharply on disappointing Ph III MARIANNE study

22 December 2014

Swiss pharma major Roche (ROG: SIX) saw its shares plunge 6.4% to 270.40 Swiss francs on Friday following release of disappointing Phase III trial results with its new cancer treatment Kadcyla (ado-trastuzumab emtansine), intended to be a successor to its blockbuster Herceptin (trastuzumab), which is beginning to face biosimilars competition.

Roche subsidiary Genentech released top-line results of the Phase III MARIANNE study, which evaluated three HER2-targeted regimens - Kadcylaplus Perjeta(pertuzumab, also from Roche), Kadcyla alone, and Herceptin(trastuzumab) plus taxane chemotherapy – in people with previously untreated (first-line) advanced HER2-positive breast cancer.

Study did not meet PFS superiority endpoint for Kadcyla-containing regimens

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK